{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:16:04Z","timestamp":1739510164227,"version":"3.37.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Soluble lectin-like oxidised low-density lipoprotein receptor 1 (sLOX-1) is overproduced during inflammation, with its expression and release triggered by C-reactive protein (CRP). As CRP levels are typically elevated in sepsis, this study aimed to investigate whether sLOX-1 levels increase in parallel.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Plasma sLOX-1 levels of 52 patients with systemic inflammatory response syndrome (SIRS), 45 patients with sepsis, 88 patients with septic shock and 37 controls were measured by ELISA. Associations with CRP, underlying diseases, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and bacterial infections were analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Plasma sLOX-1 levels were similarly elevated in patients with SIRS, sepsis, or septic shock compared to controls. Plasma sLOX-1 levels did not differ between male and female controls or patients. Plasma sLOX-1 levels were comparable in patients infected with SARS-CoV-2, Gram-negative bacteria, or Gram-positive bacteria. No association was observed between sLOX-1 levels and underlying liver cirrhosis or pancreatitis. Notably, plasma sLOX-1 levels correlated positively with leukocyte and basophil counts but showed no correlation with CRP or procalcitonin. Of clinical relevance, positive correlations were also found with aspartate aminotransferase (AST) and bilirubin levels. Among the 41 patients who did not survive, sLOX-1, AST, and bilirubin levels were significantly higher compared to those of survivors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Plasma levels of sLOX-1 are elevated in patients with SIRS or sepsis and are significantly higher in non-survivors. Of note, they do not correlate with classical inflammatory markers, suggesting that sLOX-1 may function as an independent prognostic biomarker for predicting poor outcomes in patients with SIRS or sepsis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12944-025-02462-4","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:11:24Z","timestamp":1739441484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated plasma soluble lectin-like oxidised low-density lipoprotein receptor 1 as an independent prognostic biomarker in sepsis"],"prefix":"10.1186","volume":"24","author":[{"given":"Patricia","family":"Mester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Birner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jama.1995.03520260077036","volume":"273","author":"RC Bone","year":"1995","unstructured":"Bone RC. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273:155\u20136.","journal-title":"JAMA"},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1258\/0007142991902295","volume":"55","author":"JM Gutteridge","year":"1999","unstructured":"Gutteridge JM, Mitchell J. Redox imbalance in the critically ill. Br Med Bull. 1999;55:49\u201375.","journal-title":"Br Med Bull"},{"key":"2462_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3164\/jcbn.17-130","volume":"63","author":"J Yamaguchi","year":"2018","unstructured":"Yamaguchi J, Nagase M, Yamamoto Y, Sakurai A, Kubo A, Mitsuhashi H, Matsuoka M, Ihara S, Kinoshita K. Increased oxidative stress and renal injury in patients with sepsis. J Clin Biochem Nutr. 2018;63:137\u201343.","journal-title":"J Clin Biochem Nutr"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bjid.2020.09.004","volume":"24","author":"G Sygitowicz","year":"2020","unstructured":"Sygitowicz G, Sitkiewicz D. Molecular mechanisms of organ damage in sepsis: an overview. Braz J Infect Dis. 2020;24:552\u201360.","journal-title":"Braz J Infect Dis"},{"key":"2462_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/00004872-200018060-00002","volume":"18","author":"NS Dhalla","year":"2000","unstructured":"Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655\u201373.","journal-title":"J Hypertens"},{"key":"2462_CR7","doi-asserted-by":"crossref","unstructured":"Punzo A, Silla A, Fogacci F, Perillo M, Cicero AFG, Caliceti C. Bile acids and bilirubin role in oxidative stress and inflammation in Cardiovascular diseases. Diseases 2024;12.","DOI":"10.3390\/diseases12050103"},{"key":"2462_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jcrc.2008.09.002","volume":"23","author":"M Behnes","year":"2008","unstructured":"Behnes M, Brueckmann M, Liebe V, Liebetrau C, Lang S, Putensen C, Borggrefe M, Hoffmann U. Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis. J Crit Care. 2008;23:537\u201341.","journal-title":"J Crit Care"},{"key":"2462_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/386073a0","volume":"386","author":"T Sawamura","year":"1997","unstructured":"Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73\u20137.","journal-title":"Nature"},{"key":"2462_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10557-011-6324-6","volume":"25","author":"R Yoshimoto","year":"2011","unstructured":"Yoshimoto R, Fujita Y, Kakino A, Iwamoto S, Takaya T, Sawamura T. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther. 2011;25:379\u201391.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33549\/physiolres.930043","volume":"50","author":"A Steinerova","year":"2001","unstructured":"Steinerova A, Racek J, Stozicky F, Zima T, Fialova L, Lapin A. Antibodies against oxidized LDL\u2013theory and clinical use. Physiol Res. 2001;50:131\u201341.","journal-title":"Physiol Res"},{"key":"2462_CR12","first-page":"1","volume":"69","author":"LA Campbell","year":"2013","unstructured":"Campbell LA, Lee AW, Rosenfeld ME, Kuo CC. Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1. Pathog Dis. 2013;69:1\u20136.","journal-title":"Pathog Dis"},{"key":"2462_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.it.2019.10.002","volume":"40","author":"V Guerrini","year":"2019","unstructured":"Guerrini V, Gennaro ML. Foam cells: one size doesn\u2019t fit all. Trends Immunol. 2019;40:1163\u201379.","journal-title":"Trends Immunol"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/01.ATV.20.3.715","volume":"20","author":"T Murase","year":"2000","unstructured":"Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol. 2000;20:715\u201320.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2462_CR15","first-page":"1011","volume":"38","author":"RC Ikeagwulonu","year":"2021","unstructured":"Ikeagwulonu RC, Ugwu NI, Ezeonu CT, Ikeagwulonu ZC, Uro-Chukwu HC, Asiegbu UV, Obu DC, Briggs DC. C-Reactive protein and Covid-19 severity: a systematic review. West Afr J Med. 2021;38:1011\u201323.","journal-title":"West Afr J Med"},{"key":"2462_CR16","doi-asserted-by":"crossref","unstructured":"Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med 2023.","DOI":"10.1515\/cclm-2023-0086"},{"key":"2462_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1194\/jlr.M015156","volume":"52","author":"XQ Zhao","year":"2011","unstructured":"Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, Bu PL, Yang JM, Liu XL, Zhang MX, et al. CRP enhances soluble LOX-1 release from macrophages by activating TNF-alpha converting enzyme. J Lipid Res. 2011;52:923\u201333.","journal-title":"J Lipid Res"},{"key":"2462_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/idr16040045","volume":"16","author":"P Mester","year":"2024","unstructured":"Mester P, Amend P, Schmid S, Wenzel JJ, Horing M, Liebisch G, Krautbauer S, Muller M, Buechler C, Pavel V. Proprotein Convertase Subtilisin\/Kexin type 9 induction in COVID-19 is poorly Associated with Disease severity and cholesterol levels. Infect Dis Rep. 2024;16:593\u2013607.","journal-title":"Infect Dis Rep"},{"key":"2462_CR19","doi-asserted-by":"crossref","unstructured":"Mester P, Amend P, Schmid S, Muller M, Buechler C, Pavel V. Plasma Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) as a possible biomarker for severe COVID-19. Viruses 2023;15.","DOI":"10.3390\/v15071511"},{"key":"2462_CR20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.2174\/0929867328666210714160343","volume":"29","author":"L Magnasco","year":"2022","unstructured":"Magnasco L, Sepulcri C, Antonello RM, Di Bella S, Labate L, Luzzati R, Giacobbe DR, Bassetti M. The role of PCSK9 in Infectious diseases. Curr Med Chem. 2022;29:1000\u201315.","journal-title":"Curr Med Chem"},{"key":"2462_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","volume":"8","author":"JH Boyd","year":"2016","unstructured":"Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR. Increased plasma PCSK9 levels are Associated with reduced endotoxin clearance and the development of Acute Organ failures during Sepsis. J Innate Immun. 2016;8:211\u201320.","journal-title":"J Innate Immun"},{"key":"2462_CR22","doi-asserted-by":"crossref","unstructured":"Grewal T, Buechler C. Emerging insights on the diverse roles of Proprotein Convertase Subtilisin\/Kexin type 9 (PCSK9) in Chronic Liver diseases: cholesterol metabolism and Beyond. Int J Mol Sci 2022;23.","DOI":"10.3390\/ijms23031070"},{"key":"2462_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","volume":"107","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, Shmookler Reis RJ, Varughese KI, Sawamura T, Mehta JL. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107:556\u201367.","journal-title":"Cardiovasc Res"},{"key":"2462_CR24","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.7150\/ijms.63065","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guo X, Zhang Q, Du G, Zeng Z, Zheng C, Wei Y. Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression. Int J Med Sci. 2021;18:3652\u201364.","journal-title":"Int J Med Sci"},{"key":"2462_CR25","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.3748\/wjg.v21.i26.8096","volume":"21","author":"O Ozturk","year":"2015","unstructured":"Ozturk O, Colak Y, Senates E, Yilmaz Y, Ulasoglu C, Doganay L, Ozkanli S, Oltulu YM, Coskunpinar E, Tuncer I. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21:8096\u2013102.","journal-title":"World J Gastroenterol"},{"key":"2462_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12944-024-02092-2","volume":"23","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wu L, Zhu X, Bian H, Gao X, Xia M. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics. Lipids Health Dis. 2024;23:95.","journal-title":"Lipids Health Dis"},{"key":"2462_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.diagmicrobio.2004.11.014","volume":"51","author":"WB Park","year":"2005","unstructured":"Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS, Oh MD, Choe KW. Production of C-reactive protein in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagn Microbiol Infect Dis. 2005;51:227\u201330.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2462_CR28","first-page":"113","volume":"27","author":"G Pieri","year":"2014","unstructured":"Pieri G, Agarwal B, Burroughs AK. C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol. 2014;27:113\u201320.","journal-title":"Ann Gastroenterol"},{"key":"2462_CR29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12072-022-10473-x","volume":"17","author":"B Gurbuz","year":"2023","unstructured":"Gurbuz B, Guldiken N, Reuken P, Fu L, Remih K, Preisinger C, Bruha R, Lenicek M, Petrtyl J, Reissing J, et al. Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis. Hepatol Int. 2023;17:698\u2013708.","journal-title":"Hepatol Int"},{"key":"2462_CR30","doi-asserted-by":"crossref","unstructured":"Peschel G, Grimm J, Gulow K, Muller M, Buechler C, Weigand K. Chemerin is a Valuable Biomarker in patients with HCV infection and correlates with Liver Injury. Diagnostics (Basel) 2020;10.","DOI":"10.3390\/diagnostics10110974"},{"key":"2462_CR31","doi-asserted-by":"publisher","first-page":"e14328","DOI":"10.1111\/eci.14328","volume":"55","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel A, Ciornolutchii V, Herrera TE, Ismaiel M, Leucuta DC, Popa SL, Dumitrascu DL. Adiponectin as a biomarker in liver cirrhosis-A systematic review and meta-analysis. Eur J Clin Invest. 2025;55:e14328.","journal-title":"Eur J Clin Invest"},{"key":"2462_CR32","doi-asserted-by":"publisher","first-page":"e013803","DOI":"10.1161\/JAHA.119.013803","volume":"9","author":"A Hofmann","year":"2020","unstructured":"Hofmann A, Brunssen C, Wolk S, Reeps C, Morawietz H, Soluble. LOX-1: a novel biomarker in patients with coronary artery Disease, Stroke, and Acute Aortic Dissection? J Am Heart Assoc. 2020;9:e013803.","journal-title":"J Am Heart Assoc"},{"key":"2462_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1155\/2013\/716325","volume":"35","author":"A Pirillo","year":"2013","unstructured":"Pirillo A, Catapano AL. Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases. Dis Markers. 2013;35:413\u20138.","journal-title":"Dis Markers"},{"key":"2462_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fcell.2019.00108","volume":"7","author":"C Nedeva","year":"2019","unstructured":"Nedeva C, Menassa J, Puthalakath H. Sepsis: inflammation is a necessary evil. Front Cell Dev Biol. 2019;7:108.","journal-title":"Front Cell Dev Biol"},{"key":"2462_CR35","doi-asserted-by":"publisher","first-page":"752612","DOI":"10.3389\/fimmu.2021.752612","volume":"12","author":"B Combadiere","year":"2021","unstructured":"Combadiere B, Adam L, Guillou N, Quentric P, Rosenbaum P, Dorgham K, Bonduelle O, Parizot C, Sauce D, Mayaux J, et al. LOX-1-Expressing immature neutrophils identify critically-ill COVID-19 patients at risk of thrombotic complications. Front Immunol. 2021;12:752612.","journal-title":"Front Immunol"},{"key":"2462_CR36","doi-asserted-by":"crossref","unstructured":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus. Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864\u2013\u200974.","DOI":"10.1097\/00003246-199206000-00025"},{"key":"2462_CR37","unstructured":"https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2017\/Ausgaben\/37_17.pdf?__blob=publicationFile"},{"key":"2462_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s13054-014-0529-6","volume":"18","author":"PE Marik","year":"2014","unstructured":"Marik PE. Don\u2019t miss the diagnosis of sepsis! Crit Care. 2014;18:529.","journal-title":"Crit Care"},{"key":"2462_CR39","doi-asserted-by":"crossref","unstructured":"Sheldon IM. Detection of pathogens in blood for diagnosis of Sepsis and Beyond. EBioMedicine. 2016;9:13\u20134.","DOI":"10.1016\/j.ebiom.2016.06.030"},{"key":"2462_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijid.2020.11.168","volume":"103","author":"Y Umemura","year":"2021","unstructured":"Umemura Y, Ogura H, Takuma K, Fujishima S, Abe T, Kushimoto S, Hifumi T, Hagiwara A, Shiraishi A, Otomo Y, et al. Current spectrum of causative pathogens in sepsis: a prospective nationwide cohort study in Japan. Int J Infect Dis. 2021;103:343\u201351.","journal-title":"Int J Infect Dis"},{"key":"2462_CR41","doi-asserted-by":"publisher","first-page":"e27523","DOI":"10.1016\/j.heliyon.2024.e27523","volume":"10","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Wang Y, Kang Y, Wu G, He J, Wang Z, Yang J, Wang Y, Yang X, Jia W. A retrospective study of the detection of sepsis pathogens comparing blood culture and culture-independent digital PCR. Heliyon. 2024;10:e27523.","journal-title":"Heliyon"},{"key":"2462_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/21505594.2016.1140296","volume":"7","author":"V Del Bono","year":"2016","unstructured":"Del Bono V, Giacobbe DR. Bloodstream infections in internal medicine. Virulence. 2016;7:353\u201365.","journal-title":"Virulence"},{"key":"2462_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1373\/jalm.2018.026245","volume":"3","author":"LE Huerta","year":"2019","unstructured":"Huerta LE, Rice TW. Pathologic difference between Sepsis and Bloodstream infections. J Appl Lab Med. 2019;3:654\u201363.","journal-title":"J Appl Lab Med"},{"key":"2462_CR44","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/idr16050062","volume":"16","author":"C Birner","year":"2024","unstructured":"Birner C, Mester P, Liebisch G, Horing M, Schmid S, Muller M, Pavel V, Buechler C. Lipid metabolism disorders as Diagnostic biosignatures in Sepsis. Infect Dis Rep. 2024;16:806\u201319.","journal-title":"Infect Dis Rep"},{"key":"2462_CR45","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.jlr.2021.100050","volume":"62","author":"M Horing","year":"2021","unstructured":"Horing M, Ejsing CS, Krautbauer S, Ertl VM, Burkhardt R, Liebisch G. Accurate quantification of lipid species affected by isobaric overlap in Fourier-transform mass spectrometry. J Lipid Res. 2021;62:100050.","journal-title":"J Lipid Res"},{"key":"2462_CR46","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","volume":"45","author":"W Khovidhunkit","year":"2004","unstructured":"Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169\u201396.","journal-title":"J Lipid Res"},{"key":"2462_CR47","doi-asserted-by":"publisher","first-page":"104981","DOI":"10.1016\/j.ebiom.2024.104981","volume":"100","author":"R Taylor","year":"2024","unstructured":"Taylor R, Zhang C, George D, Kotecha S, Abdelghaffar M, Forster T, Santos Rodrigues PD, Reisinger AC, White D, Hamilton F, et al. Low circulatory levels of total cholesterol, HDL-C and LDL-C are associated with death of patients with sepsis and critical illness: systematic review, meta-analysis, and perspective of observational studies. EBioMedicine. 2024;100:104981.","journal-title":"EBioMedicine"},{"key":"2462_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.202105-1197TR","volume":"205","author":"DA Hofmaenner","year":"2022","unstructured":"Hofmaenner DA, Kleyman A, Press A, Bauer M, Singer M. The many roles of cholesterol in Sepsis: a review. Am J Respir Crit Care Med. 2022;205:388\u201396.","journal-title":"Am J Respir Crit Care Med"},{"key":"2462_CR49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3947\/ic.2022.0162","volume":"54","author":"JH Kim","year":"2022","unstructured":"Kim JH. Clinical utility of Procalcitonin on antibiotic stewardship: a narrative review. Infect Chemother. 2022;54:610\u201320.","journal-title":"Infect Chemother"},{"key":"2462_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13054-020-02993-5","volume":"24","author":"C Pierrakos","year":"2020","unstructured":"Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020;24:287.","journal-title":"Crit Care"},{"key":"2462_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2008.04.002","volume":"202","author":"H Mitsuoka","year":"2009","unstructured":"Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, Jinnai T, Nishi E, Kita T. Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). Atherosclerosis. 2009;202:176\u201382.","journal-title":"Atherosclerosis"},{"key":"2462_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10238-015-0390-1","volume":"16","author":"L Vavrova","year":"2016","unstructured":"Vavrova L, Rychlikova J, Mrackova M, Novakova O, Zak A, Novak F. Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin. Clin Exp Med. 2016;16:557\u201369.","journal-title":"Clin Exp Med"},{"key":"2462_CR53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5551\/jat.3228","volume":"17","author":"T Navarra","year":"2010","unstructured":"Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317\u201331.","journal-title":"J Atheroscler Thromb"},{"key":"2462_CR54","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1124\/mol.112.078915","volume":"82","author":"S Matarazzo","year":"2012","unstructured":"Matarazzo S, Quitadamo MC, Mango R, Ciccone S, Novelli G, Biocca S. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol Pharmacol. 2012;82:246\u201354.","journal-title":"Mol Pharmacol"},{"key":"2462_CR55","doi-asserted-by":"crossref","unstructured":"Grewal T, Nguyen MKL, Buechler C. Cholesterol and COVID-19-therapeutic opportunities at the host\/virus interface during cell entry. Life Sci Alliance 2024;7.","DOI":"10.26508\/lsa.202302453"},{"key":"2462_CR56","doi-asserted-by":"crossref","unstructured":"Garcia-Rodriguez J, Janvier F, Kill C. Key insights into respiratory virus testing: sensitivity and clinical implications. Microorganisms 2025;13.","DOI":"10.3390\/microorganisms13010063"},{"key":"2462_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1478-3231.2008.01716.x","volume":"28","author":"J Fevery","year":"2008","unstructured":"Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28:592\u2013605.","journal-title":"Liver Int"},{"key":"2462_CR58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jcrc.2017.01.017","volume":"40","author":"C Pierrakos","year":"2017","unstructured":"Pierrakos C, Velissaris D, Felleiter P, Antonelli M, Vanhems P, Sakr Y, Vincent JL, investigators EI. Increased mortality in critically ill patients with mild or moderate hyperbilirubinemia. J Crit Care. 2017;40:31\u20135.","journal-title":"J Crit Care"},{"key":"2462_CR59","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.33549\/physiolres.933581","volume":"66","author":"L Vitek","year":"2017","unstructured":"Vitek L. Bilirubin and atherosclerotic diseases. Physiol Res. 2017;66:S11\u201320.","journal-title":"Physiol Res"},{"key":"2462_CR60","doi-asserted-by":"publisher","first-page":"12490","DOI":"10.1038\/s41598-021-92033-1","volume":"11","author":"TK Oh","year":"2021","unstructured":"Oh TK, Jang ES, Song IA. Long-term mortality due to infection associated with elevated liver enzymes: a population-based cohort study. Sci Rep. 2021;11:12490.","journal-title":"Sci Rep"},{"key":"2462_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.14218\/JCTH.2017.00027","volume":"5","author":"M Malakouti","year":"2017","unstructured":"Malakouti M, Kataria A, Ali SK, Schenker S. Elevated liver enzymes in asymptomatic patients - what should I do? J Clin Transl Hepatol. 2017;5:394\u2013403.","journal-title":"J Clin Transl Hepatol"},{"key":"2462_CR62","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1016\/j.atherosclerosis.2021.06.641","volume":"331","author":"S Kraler","year":"2021","unstructured":"Kraler S, Akhmedov A, Cydecian R, Liberale L, Obeid S, Von Eckardstein A, Mach F, Matter C, L\u00fcscher TF. Soluble Lox-1 and its interplay with Hs-Crp Predict Poor Cardiovascular Survival in Acute Coronary syndromes: a Multicentre prospective cohort study. Atherosclerosis. 2021;331:E209\u2013E.","journal-title":"Atherosclerosis"},{"key":"2462_CR63","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/eurheartj\/ehac143","volume":"43","author":"S Kraler","year":"2022","unstructured":"Kraler S, Wenzl FA, Georgiopoulos G, Obeid S, Liberale L, von Eckardstein A, Muller O, Mach F, Raber L, Losdat S, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur Heart J. 2022;43:1849\u201360.","journal-title":"Eur Heart J"},{"key":"2462_CR64","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1253\/circj.CJ-09-0924","volume":"74","author":"N Kume","year":"2010","unstructured":"Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome\u2013a pilot study. Circ J. 2010;74:1399\u2013404.","journal-title":"Circ J"},{"key":"2462_CR65","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1128\/IAI.01317-10","volume":"79","author":"Z Wu","year":"2011","unstructured":"Wu Z, Sawamura T, Kurdowska AK, Ji HL, Idell S, Fu J. LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect Immun. 2011;79:2865\u201370.","journal-title":"Infect Immun"},{"key":"2462_CR66","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11745-008-3227-9","volume":"43","author":"V Lubrano","year":"2008","unstructured":"Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G. Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids. 2008;43:945\u201350.","journal-title":"Lipids"},{"key":"2462_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4314\/ahs.v22i3.37","volume":"22","author":"MSA Sheikh","year":"2022","unstructured":"Sheikh MSA. Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 acts as a new biomarker for NSTEMI and STEMI patients. Afr Health Sci. 2022;22:349\u201358.","journal-title":"Afr Health Sci"},{"key":"2462_CR68","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jjcc.2010.05.002","volume":"56","author":"N Kume","year":"2010","unstructured":"Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome\u2013comparison with other biomarkers. J Cardiol. 2010;56:159\u201365.","journal-title":"J Cardiol"},{"key":"2462_CR69","doi-asserted-by":"crossref","unstructured":"Kott KA, Genetzakis E, Gray MP, Hansen P, McGuire HM, Yang JY, Grieve SM, Vernon ST, Figtree GA. Serum Soluble Lectin-like oxidized low-density lipoprotein Receptor-1 (sLOX-1) is Associated with Atherosclerosis Severity in Coronary Artery Disease. Biomolecules 2023;13.","DOI":"10.3390\/biom13081187"},{"key":"2462_CR70","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1194\/jlr.M700551-JLR200","volume":"49","author":"KC Tan","year":"2008","unstructured":"Tan KC, Shiu SW, Wong Y, Leng L, Bucala R. Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res. 2008;49:1438\u201344.","journal-title":"J Lipid Res"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02462-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02462-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:41:58Z","timestamp":1739443318000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02462-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02462-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethical committee of the University Hospital of Regensburg (18-1029-101) and was performed according to the updated guidelines of good clinical practice and the updated Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}